Panagora Asset Management Lifted Archer (ADM) Position; Clovis Oncology (CLVS) Sentiment Is 1.14

Clovis Oncology, Inc. (NASDAQ:CLVS) Logo

Panagora Asset Management Inc increased Archer (ADM) stake by 45.38% reported in 2018Q3 SEC filing. Panagora Asset Management Inc acquired 19,660 shares as Archer (ADM)’s stock declined 10.28%. The Panagora Asset Management Inc holds 62,983 shares with $3.17M value, up from 43,323 last quarter. Archer now has $24.15 billion valuation. The stock decreased 0.69% or $0.3 during the last trading session, reaching $43.07. About 1.55M shares traded. Archer-Daniels-Midland Company (NYSE:ADM) has risen 7.94% since January 11, 2018 and is uptrending. It has outperformed by 7.94% the S&P500. Some Historical ADM News: 20/04/2018 – RPT-EXCLUSIVE-U.S. sorghum armada U-turns at sea after China tariffs; 16/05/2018 – ADM SEES HISTORICAL TAX BILL DECLINING ON NEW TAX LAW; 19/03/2018 – ARCHER DANIELS MIDLAND CO – STEFANO RETTORE HAS BEEN NAMED SENIOR VICE PRESIDENT AND PRESIDENT, ORIGINATION; 12/03/2018 – Agri Marketing: ADM, BUNGE’S TALKS HAVE STALLED; 06/03/2018 – BANGKOK — China’s land reclamation and militarization of islands in the South China Sea lacks transparency and is causing angst in the Indo-Pacific region, according to Vice Adm. Philip Saywer, commander of the U.S. Navy’s 7th Fleet. In a telephone briefing on Tuesday, one day after a U.S; 16/05/2018 – ADM MAY LOOK AT ORGANIC EXPANSION, BOLT-ON ACQUISITIONS IN ANIMAL NUTRITION IN ASIA, SOUTH AMERICA -CFO; 16/05/2018 – ADM can manage supply chain through U.S.-China trade tensions -CFO; 17/04/2018 – China fans trade dispute with hefty deposit on U.S. sorghum imports; 25/04/2018 – U.S. sorghum ship switches destination from Asia to Las Palmas – Eikon data; 27/04/2018 – ADM to expand production in Bulgaria with new facility

Clovis Oncology Inc (CLVS) investors sentiment decreased to 1.14 in 2018 Q3. It’s down -0.03, from 1.17 in 2018Q2. The ratio dived, as 88 active investment managers increased or started new positions, while 77 decreased and sold their stakes in Clovis Oncology Inc. The active investment managers in our database now possess: 53.65 million shares, up from 52.83 million shares in 2018Q2. Also, the number of active investment managers holding Clovis Oncology Inc in top ten positions was flat from 2 to 2 for the same number . Sold All: 30 Reduced: 47 Increased: 59 New Position: 29.

The stock decreased 2.28% or $0.56 during the last trading session, reaching $24.24. About 1.02M shares traded. Clovis Oncology, Inc. (CLVS) has declined 63.47% since January 11, 2018 and is downtrending. It has underperformed by 63.47% the S&P500. Some Historical CLVS News: 08/05/2018 – CLOVIS ONCOLOGY 1Q LOSS/SHR $1.54, EST. LOSS/SHR $1.36; 15/04/2018 – ASTRAZENECA, MERCK & CO.: LYNPARZA MEDIAN SURVIVAL 19.3 MONTHS; 20/04/2018 – DJ Clovis Oncology Inc, Inst Holders, 1Q 2018 (CLVS); 06/04/2018 – CLOVIS ONCOLOGY SAYS U.S. FDA APPROVED RUBRACA TABLETS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CERTAIN TYPES OF RECURRENT CANCER; 29/05/2018 – Clovis Oncology Announces European Commission Authorization of Rubraca (rucaparib) for Women With Recurrent Ovarian Cancer; 09/04/2018 – Clovis Oncology Closes Above 50-Day Moving Average: Technicals; 03/04/2018 – MERCK & CO INC – ANNOUNCED THAT EUROPEAN MEDICINES AGENCY HAS VALIDATED FOR REVIEW MARKETING AUTHORIZATION APPLICATION FOR LYNPARZA; 11/04/2018 – STAT Plus: SEC considers civil charges against Clovis Oncology over trial data for discarded drug; 15/05/2018 – Healthcor Management LP Exits Position in Clovis Oncology; 06/04/2018 – Clovis Oncology: FDA Converted Approval of the Initial Treatment Indication From Accelerated to Regular Approval

Opus Point Partners Management Llc holds 5.78% of its portfolio in Clovis Oncology, Inc. for 82,430 shares. Armistice Capital Llc owns 1.64 million shares or 2.88% of their US portfolio. Moreover, Kazazian Asset Management Llc has 2.86% invested in the company for 104,116 shares. The California-based Redmile Group Llc has invested 1.61% in the stock. Venbio Select Advisor Llc, a California-based fund reported 1.15 million shares.

More notable recent Clovis Oncology, Inc. (NASDAQ:CLVS) news were published by: Nasdaq.com which released: “Do Options Traders Know Something About Clovis (CLVS) Stock We Don’t? – Nasdaq” on December 14, 2018, also Seekingalpha.com with their article: “Clovis down 7% on diminished prospects for takeover – Seeking Alpha” published on December 14, 2018, Nasdaq.com published: “Noteworthy Friday Option Activity: CLVS, ABBV, AAL – Nasdaq” on December 21, 2018. More interesting news about Clovis Oncology, Inc. (NASDAQ:CLVS) were released by: Nasdaq.com and their article: “Detailed Research: Economic Perspectives on Canopy Growth, ArQule, MoneyGram International, Teradata, Clovis Oncology, and Axovant Sciences — What Drives Growth in Today’s Competitive Landscape – Nasdaq” published on December 26, 2018 as well as Streetinsider.com‘s news article titled: “Clovis Oncology’s (CLVS) Rubraca Receives Positive CHMP Opinion – StreetInsider.com” with publication date: December 13, 2018.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has market cap of $1.28 billion. The Company’s commercial product includes Rubraca tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. It currently has negative earnings. The firm is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications.

Analysts await Clovis Oncology, Inc. (NASDAQ:CLVS) to report earnings on February, 25. They expect $-1.74 earnings per share, down 37.01% or $0.47 from last year’s $-1.27 per share. After $-1.71 actual earnings per share reported by Clovis Oncology, Inc. for the previous quarter, Wall Street now forecasts 1.75% negative EPS growth.

Since January 1, 0001, it had 0 buys, and 5 insider sales for $60,638 activity.

More notable recent Archer-Daniels-Midland Company (NYSE:ADM) news were published by: Seekingalpha.com which released: “Archer Daniels Midland makes a citrus play – Seeking Alpha” on January 11, 2019, also Businesswire.com with their article: “ADM Recognized for Efforts to Promote Workplace Diversity in Ag – Business Wire” published on December 18, 2018, Streetinsider.com published: “Pre-Open Stock Movers 01/11: (FTK) (TLRY) (GM) Higher; (MTN) (PCG) (ATVI) Lower (more…) – StreetInsider.com” on January 11, 2019. More interesting news about Archer-Daniels-Midland Company (NYSE:ADM) were released by: Streetinsider.com and their article: “US ethanol producers seek pricing reform as markets plunge, ADM sells – StreetInsider.com” published on December 17, 2018 as well as Seekingalpha.com‘s news article titled: “Bottom line improvement at Archer Daniels Midland – Seeking Alpha” with publication date: November 06, 2018.

Among 4 analysts covering Archer-Daniels Midland (NYSE:ADM), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Archer-Daniels Midland had 4 analyst reports since August 1, 2018 according to SRatingsIntel. The rating was maintained by BMO Capital Markets with “Market Perform” on Wednesday, August 1. The stock of Archer-Daniels-Midland Company (NYSE:ADM) earned “Buy” rating by Buckingham Research on Wednesday, August 1. Morgan Stanley maintained the shares of ADM in report on Friday, August 3 with “Equal-Weight” rating. The rating was upgraded by Argus Research to “Buy” on Thursday, November 8.

Panagora Asset Management Inc decreased Charles River Laboratories (NYSE:CRL) stake by 9,079 shares to 194,200 valued at $26.13M in 2018Q3. It also reduced Antares Pharma Inc (NASDAQ:ATRS) stake by 1.30M shares and now owns 460 shares. Quest Diagnostics Inc (NYSE:DGX) was reduced too.

Since August 1, 2018, it had 1 insider buy, and 4 sales for $5.18 million activity. Young Ray G had bought 2,100 shares worth $99,429. D AMBROSE MICHAEL sold 100,151 shares worth $4.84M. 2,500 shares were sold by Stott John P, worth $130,000. 3,847 shares valued at $196,235 were sold by Taets Joseph D. on Monday, August 20.

Archer-Daniels-Midland Company (NYSE:ADM) Institutional Positions Chart